Bromobenzene → (4-Cyclobutylpiperazin-1-yl)-(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone

HRID 674

反応式

HRID 674 の反応式
Brc1ccccc1.O=C(C1CC2(CCNCC2)C1)N1CCN(C2CCC2)CC1>CC(=O)O.CC(=O)O.Cc1ccccc1.O=C([O-])[O-].[Cs+].[Cs+].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>O=C(C1CC2(CCN(c3ccccc3)CC2)C1)N1CCN(C2CCC2)CC1

参加物

7

反応条件

温度
110 °C

実験手順

cesium carbonate (123 mg, 0.38 mmol) was added to a solution of (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (100 mg, 0.34 mmol), PdOAc2 (7.70 mg, 0.03 mmol), BINAP (42.7 mg, 0.07 mmol) and bromobenzene (56.6 mg, 0.36 mmol) in toluene (5 mL). The reaction mixture was heated to 110°C for 18hrs. The room temperature cooled down mixture was filtered over celite. The solvent was concentrated. The product was purified by preparative HPLC using a low pH shallow gradient method (Mobile phase: 20-40% B; A: H2O with 0.05% TFA , B: CH3CN, 25 min. run) on Luna 15 m, C8 (2), 21.2x250 mm Phenomenex reverse phase column to provide (4-cyclobutylpiperazin-1-yl)(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone (59.0 mg, 46.8 %) as white solid. 1H NMR (400 MHz, CHLOROFORM- _d_ ) d ppm 1.60 - 1.75 (m, 4 H) 1.75 - 1.81 (m, 2 H) 1.81 - 1.95 (m, 2 H) 1.96 - 2.10 (m, 4 H) 2.10 - 2.20 (m, 2 H) 2.21 - 2.35 (m, 4 H) 2.71 (dq, _J_ =8.01, 7.75 Hz, 1 H) 3.00 - 3.11 (m, 2 H) 3.11 - 3.26 (m, 3 H) 3.31 - 3.42 (m, 2 H) 3.56 - 3.70 (m, 2 H) 6.82 (t, _J_ =7.23 Hz, 1 H) 6.93 (d, _J_ =7.81 Hz, 2 H) 7.18 - 7.29 (m, 2 H) HRMS _m/z_ calcd for C23H33N3O 368.26964 [M+H]+, found 368.26981. MS _m/z_ 368.3 [M+H]\+ (ES+)

出典と根拠

ORDレコード
ord-2bde997c68344c96991dffb75b1f4b33
出典データセット
750 AstraZeneca ELN dataset
元リンク
出典を表示

関連ノート

読み込み中…